Proteomics International says it has secured a key Australian patent covering its PromarkerEndo test for diagnosing endometriosis.
The company frames the development as an important step in its broader commercialisation plans, including efforts to market the diagnostic internationally. Each outlet reports the same core details: the patent is described as “key” and is specifically linked to the PromarkerEndo endometriosis test. While the coverage does not include further technical or financial specifics, the emphasis is consistent that the patent strengthens the company’s ability to pursue the test’s rollout.
Across the sources, the reporting focuses on the milestone of obtaining the Australian patent rather than on any clinical outcomes, regulatory approvals, or timelines for product availability. No outlet provides differing figures or contrasting interpretations; the emphasis remains on the patent as part of PromarkerEndo’s commercial strategy.
